Who Paid My Doc
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO
Research payments
$10,764,464
Through program year 2025, $10,764,464 in research payments was reported against A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO, across 2,637 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,464 | 1 |
| 2023 | Research | $1,363,999 | 463 |
| 2022 | Research | $4,877,771 | 505 |
| 2021 | Research | $1,981,624 | 528 |
| 2020 | Research | $2,538,606 | 1,140 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Narinder Saini Springfield, OH Named on 88 payments
- Douglas Moffett Lady Lake, FL Named on 80 payments
- Allison Hanna Bountiful, UT Named on 72 payments
- Joseph Lambert North Richland Hills, TX Named on 59 payments
- Blaise Gatto Cincinnati, OH Named on 54 payments
- Gregory Moore Richmond, VA Named on 47 payments
- Salma Saiger Mesquite, TX Named on 46 payments
- Luis Castillo Palm Springs, FL Named on 46 payments
- Jonathan Hubbard St George, UT Named on 46 payments
- Amrendra Kumar Lancaster, SC Named on 42 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.